About Adams Respiratory Therapeutics
Adams is a specialty pharmaceutical company focused on late stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders. Adams was acquired by Reckitt Benckiser in January 2008.
Missing: Adams Respiratory Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Adams Respiratory Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Adams Respiratory Therapeutics News
Jan 16, 2012
Perrigo Company (NASDAQ:PRGO) recently announced that it has won a summary judgment in the patent case involving the generic version of Adams Respiratory Therapeutics’ drug Mucinex. Adams Respiratory Therapeutics is a subsidiary of Reckitt Benckiser Group. Perrigo had received approval for its generic version of Mucinex in December 2011. It plans to launch the drug within the next 90 days. Mucinex indicated to relieve chest congestion has been identified as one of the important product … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
Adams Respiratory Therapeutics Frequently Asked Questions (FAQ)
When was Adams Respiratory Therapeutics founded?
Adams Respiratory Therapeutics was founded in 1997.
Where is Adams Respiratory Therapeutics's headquarters?
Adams Respiratory Therapeutics's headquarters is located at 4 Mill Ridge Lane, Chester.
What is Adams Respiratory Therapeutics's latest funding round?
Adams Respiratory Therapeutics's latest funding round is Acq - P2P.
How much did Adams Respiratory Therapeutics raise?
Adams Respiratory Therapeutics raised a total of $31.41M.
Who are the investors of Adams Respiratory Therapeutics?
Investors of Adams Respiratory Therapeutics include Reckitt Benckiser, Merrill, Equity Group Investments, Marquette Venture Partners, Talon Asset Management and 5 more.
Who are Adams Respiratory Therapeutics's competitors?
Competitors of Adams Respiratory Therapeutics include Neurelis, Ology Bioservices, Acura Pharmaceuticals, Charleston Laboratories, Aerogen, Collegium Pharmaceutical, Meritage Pharma, Auxilium Pharmaceuticals, Questcor Pharmaceuticals, Acton Pharmaceuticals and 20 more.
Compare Adams Respiratory Therapeutics to Competitors
IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.
P2D, Inc. is a pharmaceutical company focused on developing new pharmaceuticals for brain disorders
Pradama, Inc. is a pharmaceutical company focused on the development and commercialization of products to treat bone diseases and disorders. Pradama is developing compounds that target bone with the initial two products designed for osteoporosis treatment and an antineoplastic compound for the treatment of bone metastases.
Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.
Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.
Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.